Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Proceeding of Mulawarman Pharmaceuticals Conferences
Shofia Siza Maulidia
Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Kajian Potensi Interaksi Obat pada Pasien COVID-19 di Rumah Sakit X Kota Samarinda: Study of Potential Drug Interactions in COVID-19 Patients at Hospital X Samarinda City Shofia Siza Maulidia; Febrina Mahmudah; Yurika Sastyarina
Proceeding of Mulawarman Pharmaceuticals Conferences Vol. 14 (2021): Proceeding of Mulawarman Pharmaceuticals Conferences
Publisher : Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (304.193 KB) | DOI: 10.25026/mpc.v14i1.587

Abstract

Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease caused by a coronavirus known as SARS-CoV-2 and is currently a worldwide pandemic. Treatment management for COVID-19 patients is grouped based on the level of symptoms experienced by the patient. The use of large amounts of drugs (polypharmacy) in COVID-19 patients with moderate and severe symptoms can increase the possibility of drug interactions. This study aims to determine patient characteristics and the potential for drug interactions in COVID-19 patients at Hospital X Samarinda City. The data collection method was conducted retrospectively based on the medical records of COVID-19 patients hospitalized from March to December 2020. Data on potential drug interactions were analyzed using the Drugs.com application. The results showed that of the 30 patients with COVID-19, male-dominated (60%) and aged between 46 and 55 years (50%). Data on potential drug interactions showed that 28 out of 30 patients had the potential to experience drug interactions in the categories of severe (9,23%), moderate (74,62%), and mild (16,15%).
Co-Authors Febrina Mahmudah Yurika Sastyarina